Shandong Simcere Biopharmaceutical

Shandong Simcere Biopharmaceutical is a key subsidiary of Simcere Pharmaceutical Group, a leading R&D-driven pharmaceutical company in China. The company focuses on the development, manufacturing, and commercialization of innovative and generic drugs across oncology, central nervous system, and autoimmune therapeutic areas. One of its flagship products is Endostar, a first-in-class recombinant human endostatin for the treatment of non-small cell lung cancer. The company maintains high-standard GMP manufacturing facilities and contributes significantly to Simcere's integrated platform for drug discovery and production. Simcere is listed on the Hong Kong Stock Exchange and operates multiple R&D centers globally.